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Epstein-Barr virus (EBV) is closely associated with certain lymphoid and epithelial malignancies such as Burkitt 
lymphoma, nasopharyngeal carcinoma (NPC) and gastric carcinoma (GC). In the tumor cells, the virus persists 
in a tight latency, expressing a limited number of latent proteins. Reactivation of EBV lytic cycle from latency 
leads to expression of many more viral lytic proteins which may provide potential therapeutic targets for the 
EBV-associated cancers. Histone deacetylase (HDAC) inhibitors belong to an emerging class of anti-cancer 
agents which work through acetylation of different histone and non-histone proteins in cancer cells. Our 
previous work showed that various pan-HDAC inhibitors, which inhibit eleven HDAC isoforms, can 
preferentially reactivate EBV lytic cycle in EBV-positive epithelial rather than lymphoid cancers and mediate 
enhanced killing of EBV-positive NPC and GC cells through augmentation of apoptotic cell death. Recently, we 
found that a selective class I HDAC inhibitor, romidepsin, can potently induce EBV lytic cycle in NPC and GC 
cells and confer susceptibility of the induced cells to killing by an anti-viral agent, ganciclovir, in vitro and in 
vivo. The reactivation of EBV lytic cycle by romidepsin is related to the inhibition of HDAC-1, -2 and -3 isoforms 
and the activation of PKC-. Interestingly, our current findings suggest that acetylation of non-histone proteins 
might also play a role in the regulation of EBV lytic cycle upon HDAC inhibition. In this review, we discuss our 
recent findings on the mechanisms of EBV lytic cycle reactivation and propose possible strategies in using 
HDAC inhibitors for the treatment of EBV-associated cancers. 
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Introduction 
Epstein-Barr virus (EBV) is a ubiquitous gamma 
herpesvirus which infects more than 90% of populations 
worldwide. It is closely associated with several types of 
lymphomas (e.g. endemic Burkitt lymphoma, Hodgkin 
lymphoma, nasal NK/T-cell lymphoma and post-transplant 
lymphoproliferative disorder) and epithelial malignancies 
(nasopharyngeal carcinoma [NPC] and gastric carcinoma 
[GC]) [1, 2]. EBV has a biphasic life cycle, namely latent and 
lytic cycles. In the EBV-associated cancers, the virus persists 
in the latent cycle in every tumor cell and expresses a very 
limited number of viral latent proteins. Induction of EBV 
from its latent to lytic cycle can lead to the sequential 
expression of a series of lytic proteins, namely the immediate 
early (e.g. Zta or Rta), early (e.g. BMRF1 or BGLF1) and 
late lytic proteins (e.g. VCA-p18 and gp350/220). The 
expression of more viral lytic proteins will lead to higher 
immunogenicity and provide an opportunity for therapeutic 
targeting against the EBV-associated cancers.  
REVIEW 
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Oncolytic therapy, which involves pharmacological 
reactivation of the latent virus into lytic cycle to confer 
susceptibility of EBV-infected cells to antiviral drugs, is 
being explored as a potential therapeutic strategy against the 
EBV-associated diseases [3, 4]. Studies have shown that 
ganciclovir (GCV), a nucleoside-type antiviral drug, can 
enhance tumor cell death in combination with different types 
of lytic inducers. Since the killing effect of GCV relies on 
expression of viral lytic protein kinase BGLF4 [5], the 
efficiency and specificity of lytic induction greatly impact 
the efficacy of this treatment strategy. Understanding the 
mechanisms controlling the lytic reactivation is important for 
the development of specific and potent lytic inducing agents 
for the treatment of EBV-associated cancers. 
The summative action of histone acetyltransferases (HATs) 
and histone deacetylases (HDACs) regulates lysine 
acetylation of different cellular proteins. HATs transfer acetyl 
groups from acetyl-coenzyme A to -amino groups of lysine 
residues in the N-terminal tails of proteins whilst HDACs 
remove the acetyl groups from the lysine residues of proteins 
[6]. Lysine acetylation of histone proteins plays an important 
role in regulation of gene expression because it neutralizes 
the positive charge of histone and results in an open 
chromatin structure for expression of genes associated with 
the acetylated histones [7, 8]. It has been shown that 
acetylation of histones on the immediately-early promoter of 
human cytomegalovirus [9] and BRLF1 promoter of EBV [10] 
can result in reactivation of viral lytic cycle in the 
virus-associated cancers. On the other hand, lysine 
acetylation can also directly regulate the activities of various 
non-histone protein substrates [11, 12]. A recent study identified 
3600 acetylation sites in 1750 cellular proteins in different 
human cancer cell lines using a high resolution mass 
spectrometry analysis, suggesting the possibility of 
previously unexplored roles of protein acetylation in various 
cellular processes [12]. 
Pan-HDAC inhibitors such as trichostatin A or 
suberoylanilide hydroxamic acid (SAHA) are able to inhibit 
class I (HDAC1/2/3/8), class II (HDAC4/5/6/7/9/10) and 
class IV (HDAC11) but not NAD+ dependent class III 
HDAC isoforms [7]. We have reported that pan-HDAC 
inhibitors, such as trichostatin A, sodium butyrate, valproic 
acid and SAHA can reactivate lytic cycle of EBV and 
mediate enhanced killing of EBV-positive epithelial cancer 
cells, including NPC and GC [13, 14]. Based on the potent 
effect of HDAC inhibitors on the reactivation of viral lytic 
cycle in EBV-positive epithelial cancer cells, we endeavored 
to investigate the mechanisms by which HDAC inhibitors 
reactivate EBV lytic cycle as essential steps to translate the 
use of HDAC inhibitors for the clinical treatment of 
EBV-positive epithelial malignancies. We tested the 
hypothesis that inhibition of several specific HDAC isoforms 
by selective HDAC inhibitors can potently reactivate EBV 
lytic cycle in EBV-positive NPC and GC cells [15]. Our data 
showed that inhibition of HDAC-1, -2 and -3 by selective 
HDAC inhibitors such as romidepsin is sufficient to induce 
EBV lytic cycle in NPC and GC cells and confer 
susceptibility of the induced cells to killing by an anti-viral 
agent, ganciclovir, in vitro and in vivo [15]. These data have 
demonstrated an important role of HDAC inhibition in the 
regulation of lytic cycle reactivation and supported further 
investigation into the application of selective HDAC 
inhibitors such as romidepsin for the treatment of 
EBV-associated cancers. Our on-going work demonstrates, 
for the first time, that acetylation of non-histone proteins is 
involved in the lytic cycle reactivation by HDAC inhibitors 
in EBV-positive epithelial malignancies. 
Results and Discussion 
Our recent publication showed that a class I selective 
HDAC inhibitor, romidepsin, can potently induce EBV lytic 
cycle in EBV-positive epithelial malignanices including NPC 
and GC cells in vitro and in vivo [15]. When combined with 
ganciclovir (GCV), enhanced killing could be observed in 
the EBV-positive, but not EBV-negative NPC and GC cells 
[15]. Romidepsin is an FDA-approved drug for the treatment 
of cutaneous T-cell lymphoma and peripheral T-cell 
lymphoma [16]. The concentration of romidepsin which 
induces EBV lytic cycle (~5 nM) is much lower than the 
clinically achievable concentration in patients’ plasma (~800 
nM) [17]. These data support the use of romidepsin as a potent 
and safe lytic inducer of viral lytic cycle for the oncolytic 
therapy in EBV-associated epithelial cancers. The concept of 
the lytic induction therapy using combination of HDAC 
inhibitors, gemcitabine and GCV has been demonstrated to 
be work in clinical trials carried out in NPC patients [3, 4]. It 
would be interesting to substitute valproic acid with 
romidepsin in such clinical trials. We predict that enhanced 
clinical outcomes can be observed in NPC patients because 
the potency of EBV lytic cycle reactivation induced by 
romidepsin is much stronger than that induced by valproic 
acid (5 nM romidepsin vs 5 mM valproic acid) [13, 15]. 
However, the major hindrance to the application of oncolytic 
therapy is the presence of refractory cell population to lytic 
reactivation by current lytic inducers, including HDAC 
inhibitors. Deciphering the mechanisms regulating the switch 
from viral latent to lytic cycle in cancer cells may aid in the 
translation of oncolytic therapy for the treatment of 
EBV-associated cancers. 
We have been investigating the cellular consequences 
following EBV lytic cycle reactivation in different 
EBV-associated cancer cell lines. We observed that lytic 
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cycle induction by HDAC inhibitors could mediate enhanced 
killing of EBV-positive epithelial cells when compared with 
their EBV-negative counterparts [13]. We further found that 
the enhanced killing was related to the induction of apoptosis 
as evidenced by the co-expression of EBV lytic proteins (e.g. 
Zta) and apoptotic marker (e.g. cleaved caspase-3) in 
EBV-positive epithelial cells upon treatment with HDAC 
inhibitors (e.g. SAHA) [14]. Inhibition of EBV DNA 
replication and expression of EBV late lytic proteins by 
phosphonofomic acid did not impact on SAHA’s induced 
killing of EBV-positive epithelial cells, suggesting that 
induction of early phase of lytic cycle was sufficient to 
mediate enhanced killing of EBV-positive versus 
EBV-negative cancer cells. Such enhanced killing could not 
be observed in EBV-positive lymphoid cells (e.g. Burkitt 
lymphoma, NK/T cell lymphoma and lymphoblastoid cell 
lines) since they are not responsive to lytic cycle reactivation 
by HDAC inhibitors [13]. In these non-inducible lymphoid 
cells, we are developing other strategies to target the function 
of EBV latent proteins (e.g. EBV nuclear antigen-3A/-3C) 
[18].  
Several candidate viral lytic proteins might be involved in 
the killing of EBV-associated cancers upon treatment with 
HDAC inhibitors. For instance, the major EBV lytic cycle 
initiator Zta, which can induce phosphorylation of p53 and 
G2/M arrest, might directly cause cell death following lytic 
induction by HDAC inhibitors [19, 20]. Another lytic initiator 
Rta can also induce irreversible G1 arrest, cellular 
senescence and apoptosis in EBV-positive epithelial cancer 
cell lines [21, 22, 23]. Other early viral proteins such as the EBV 
alkaline exonuclease BGLF5, which can shut off important 
cellular gene functions and trigger apoptosis, might also be 
involved [24]. It will be interesting to investigate whether 
HDAC inhibitors can modulate the function of BHRF1, an 
EBV-encoded early lytic protein homologous to the 
anti-apoptotic protein Bcl-2, in the EBV-positive cancer cell 
lines [25-27]. Another possible mechanism of action of HDAC 
inhibitors may be the direct acetylation of cellular tumor 
suppressor protein, p53, which is known to interrupt the 
anti-apoptotic activities of Bcl-2 family members [28]. The 
activities of the anti-apoptotic EBV miR-BARTs and their 
mRNA targets (e.g. CASZ1, DICE1 and TP53INP1) in the 
NPC and GC cells upon treatment with HDAC inhibitors 
also deserve further investigation [29]. 
The roles of different HDAC isoforms (i.e., HDAC1-11) 
in the regulation of EBV lytic reactivation remain unclear. 
We showed that inhibition of HDAC-1, -2 and -3 either by 
selective HDAC inhibitors targeting HDAC-1, -2 and -3 
(romidepsin, MS-275 or apicidin) or by shRNA knockdown 
is sufficient to induce EBV lytic cycle in NPC and GC cells 
[15]. The data are consistent with the findings that 
overexpression of HDAC-2 could suppress the lytic cycle 
reactivation in NPC cells by HDAC inhibitors [30]. Class I 
HDACs such as HDAC-2 and -3 are found to be important in 
the control of lytic reactivation of other latent viruses such as 
human immunodeficiency virus (HIV) and Kaposi's 
sarcoma-associated herpesvirus (KSHV) [31, 32]. We also 
observed that HDAC-2 and -3 are overexpressed in 
EBV-positive epithelial cells when compared with 
EBV-positive lymphoid cells (unpublished data). The data 
might explain why epithelial cells are more sensitive to the 
reactivation of EBV lytic cycle by HDAC inhibitors when 
compared with lymphoid cells [13, 18]. 
Several kinase pathways, including the 
phosphatidylinositol 3’-kinase (PI3K), MAPK/ERK kinase 
(MEK), c-Jun amino terminal kinase (JNK), p38 stress 
mitogen-activated protein kinase (MAPK), ataxia 
telangiectasia-mutated (ATM) kinase, and protein kinase 
C-delta (PKC-) pathways [5, 30, 33-38] were shown to control 
the activation of EBV lytic cycle in various cancer cell types. 
We demonstrated that only PKC-, rather than PI3K, MEK, 
JNK, p38 MAPK, and ATM pathways, was related to the 
EBV lytic cycle reactivation by romidepsin [15]. The data are 
consistent with Tsai et al., 2011 which showed that the 
activation of PKC- and Sp1 was essential for the lytic cycle 
reactivation in NPC cells upon treatment with HDAC 
inhibitors [30]. Feng et al. also showed that activation of 
PKC- signaling was involved in the reactivation of EBV 
lytic cycle in GC cells by 5-FU and cisplatin [5]. However, 
our laboratory and others have demonstrated that the ATM 
pathway seems to be involved in the step of viral DNA 
replication rather than the initiation step of lytic cycle 
reactivation [39, 40], contrary to a report which showed that the 
activation of ATM pathway was crucial for the EBV lytic 
cycle reactivation [37]. Contradictory roles of PKC- 
signaling are also observed in our laboratory when we induce 
EBV lytic cycle in the NPC and GC cells by novel lytic 
inducers identified in a high-throughput screening versus 
HDAC inhibitors (unpublished data). The discrepant 
pathways of lytic reactivation suggest that resistance to EBV 
lytic reactivation might arise as a result of alteration of 
expression of various signaling molecules in different cell 
lines. A combination of pharmacological agents, which target 
multiple signaling pathways, may be required to overcome 
the resistance to lytic cycle reactivation in EBV-associated 
cancer cells. 
It remains unknown whether acetylation of histone or 
non-histone proteins or both by HDAC inhibitors is 
responsible for viral lytic cycle reactivation in EBV-positive 
epithelial malignancies. Whilst histone acetylation was 
reported to be critical in the reactivation of EBV lytic cycle, 
some laboratories showed that histone acetylation was not 
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required [41-43]. Transcription factors, such as Sp1, Sp3, 
CREB, MEF2D, C/EBPs, ZEBs and YY1, which are known 
to be associated with the EBV Z promoter (the key initiator 
of EBV lytic cycle), can be modified by lysine acetylation 
[44-50]. In addition, phosphorylation of TIP60, a HAT, was 
found to be required for EBV DNA replication [39, 51]. It will 
thus be interesting to study the roles of acetylation of 
non-histone proteins in the induction of lytic cycle of EBV. 
We have previously reported that a proteasome inhibitor, 
bortezomib, can synergize with HDAC inhibitors, including 
SAHA and romidepsin, to induce histone acetylation whilst it 
suppresses HDAC inhibitors’ activation of EBV lytic cycle in 
NPC cells [52, 53], suggesting that induction of EBV lytic cycle 
may not directly correlate to the level of histone acetylation. 
Our current work showed that HAT inhibitors, including 
garcinol and anacardic acid, can significantly suppress the 
expression of EBV immediate-early (Zta and Rta), early 
(BMRF1) and late (VCA-p18) lytic proteins induced by 
SAHA in a dose-dependent manner (unpublished data). 
Interestingly, the HAT inhibitors can suppress SAHA’s 
induction of EBV lytic cycle at a concentration that does not 
inhibit the histone acetylation of the Z promoter. On the other 
hand, the HAT inhibitors can abrogate SAHA’s acetylation of 
non-histone proteins, inferring that acetylation of non-histone 
proteins might be involved in the regulation of EBV lytic 
cycle reactivation. In fact, HDAC inhibitors are shown to 
acetylate more than 1750 cellular proteins in different human 
cancer cell lines [12]. It would be interesting to identify which 
acetylated proteins are involved in the reactivation of EBV 
lytic cycle. Zp transcription factors, such as ZEBs and YY1, 
which can be directly acetylated by HDAC inhibitors, are 
potential candidates [49, 50]. 
Our recent work demonstrated HDAC inhibitors (e.g. 
SAHA and romidepsin) are potent inducers of EBV lytic 
cycle in EBV-positive epithelial cancer cells. Furthermore, 
EBV lytic cycle induction by HDAC inhibitors can mediate 
enhanced apoptosis of the EBV-positive cells when 
compared with EBV-negative cells and render EBV-positive 
cells susceptible to killing by GCV (Figure 1). These data 
support the therapeutic value of developing HDAC inhibitors 
as potent lytic inducing drugs for oncolytic therapy against 
EBV-associated epithelial malignancies. However, a certain 
proportion of the cancer cells is refractory to lytic cycle 
reactivation. In the future, we aim to further decipher the 
mechanisms regulating the lytic cycle reactivation in 
EBV-associated cancer cells. Identification of new molecules 
or pathways involved in EBV lytic cycle induction will open 
new avenues for testing and development of drugs for 
viral-targeted therapy against EBV-associated cancers. 
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